Marta Nunes

Dr. Marta Nunes

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2003 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MNMarta Nunes
Marta Nunes
NRNeeta Singh Roy
Neeta Singh Roy
HKH. Michael Keyoung
H. Michael Keyoung
RGRobert R. Goodman
Robert R. Goodman
GMGuy McKhann
Guy McKhann
SGSteven A. Goldman
Steven A. Goldman

4 September 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SMShabir Ahmed Madhi
Shabir Ahmed Madhi
CCClare L Cutland
Clare L Cutland
LKLocadiah Kuwanda
Locadiah Kuwanda
AWAdriana Weinberg
Adriana Weinberg
AHAndrea Hugo
Andrea Hugo
MNMarta Nunes
Marta Nunes
There are limited data on the efficacy of vaccination against confirmed influenza in pregnant women with and those without human immunodeficiency virus (HIV) infection and protection of their infants.

30 January 2018 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
POPablo Obando-Pacheco
Pablo Obando-Pacheco
AJAntonio José Justicia-Grande
Antonio José Justicia-Grande
IRIrene Rivero-Calle
Irene Rivero-Calle
CRCarmen Rodríguez-Tenreiro
Carmen Rodríguez-Tenreiro
PSPeter Sly
Peter Sly
Federico Martinón-TorresFederico Martinón-Torres
Federico Martinón-Torres
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in children. By the age of 1 year, 60%–70% of children have been infected by RSV. In addition, early-life RSV infection is associated with the development of recurrent wheezing and asthma in infancy and childhood. The need for precise epidemiologic data regarding RSV as a worldwide pathogen has been growing steadily as novel RSV therapeutics are reaching the final stages of development. To optimize the prevention, diagnosis, and treatment of RSV infection in a timely manner, knowledge about the differences in the timing of the RSV epidemics worldwide is needed. Previous analyses, based on literature reviews of individual reports obtained from medical databases, have failed to provide global country seasonality patterns. Until recently, only certain countries have been recording RSV incidence through their own surveillance systems. This analysis was based on national RSV surveillance reports and medical databases from 27 countries worldwide. This is the first study to use original-source, high-quality surveillance data to establish a global, robust, and homogeneous report on global country-specific RSV seasonality.

1 October 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
NMNatalie I Mazur
Natalie I Mazur
DHDeborah Higgins
Deborah Higgins
MNMarta Nunes
Marta Nunes
JMJosé A Melero
José A Melero
ALAnnefleur C Langedijk
Annefleur C Langedijk
LBLouis J Bont
Louis J Bont
The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.

21 December 2003 in Nature Medicine
Verified
Journal Article
Closed access
MWMartha S Windrem
Martha S Windrem
MNMarta Nunes
Marta Nunes
WRWilliam K Rashbaum
William K Rashbaum
TSTheodore H Schwartz
Theodore H Schwartz
RGRobert A Goodman
Robert A Goodman
SGSteven A Goldman
Steven A Goldman

1 March 2021 in Vaccine
Verified
Journal Article
Open access
AMAlejandro E. Macias
Alejandro E. Macias
JMJanet E. McElhaney
Janet E. McElhaney
SCSandra S. Chaves
Sandra S. Chaves
JNJoshua Nealon
Joshua Nealon
MNMarta Nunes
Marta Nunes
HYHongjie Yu
Hongjie Yu
Although influenza is primarily considered a respiratory infection and causes significant respiratory mortality, evidence suggests that influenza has an additional burden due to broader consequences of the illness. Some of these broader consequences include cardiovascular events, exacerbations of chronic underlying conditions, increased susceptibility to secondary bacterial infections, functional decline, and poor pregnancy outcomes, all of which may lead to an increased risk for hospitalization and death. Although it is methodologically difficult to measure these impacts, epidemiological and interventional study designs have evolved over recent decades to better take them into account. Recognizing these broader consequences of influenza virus infection is essential to determine the full burden of influenza among different subpopulations and the value of preventive approaches. In this review, we outline the main influenza complications and societal impacts beyond the classical respiratory symptoms of the disease.